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Background: Clinical and psychosocial remission amongst persons with schizophrenia is nowadays a defined goal
of treatment. This necessitates incorporating quantifiable psychosocial variables with traditional symptomatic data.
We aimed to assess clinical and psychosocial remission in schizophrenia in a large cohort of community dwelling
persons with schizophrenia. We emphasized between-groups comparison of antipsychotic medications and
administration methods on the outcome of remission.
Methods: Psychiatric case managers rated psychosocial remission using the PsychoSocial Remission Scale (PSRS)
and clinical remission using the Remission in Schizophrenia Working Group symptomatic remission criteria (RSWG).
Ratings were performed for persons with schizophrenia they have been treating for 6 months or more. Data as to
gender, age and pharmacological treatment of each patient were also collected.
Results: Of 445 participants who completed the survey, 268 (60%) were evaluated by psychiatrists, 161 (36%) by
nurses and 16 (4%) were evaluated by social workers. Patients mean age was 43.4 + 13.1 years; 61% were men
and 39% were women. Antipsychotic treatments were as follows: Per-os (PO) 243 (55%), IM long-acting typical
antipsychotics (LAT) 102 (23%) and IM long-acting risperidone (RLAI; Consta) 100 (22%). Overall, 37% of patients
achieved symptomatic remission and 31% achieved psychosocial remission. Rates of symptomatic remission were
significantly higher in patients treated by LAT and RLAI compared with PO (51% and 48% vs., 29% respectively,
p = 0.0003). Rates of psychosocial remission were also significantly higher in patients treated by LAT and RLAI
compared with PO (43%% and 41% vs., 24% respectively, p = 0.003).
Conclusion: In a large national sample a third of persons with schizophrenia were in remission. IM long acting
preparations were associated with higher remission rates. Treatment choice may thus influence rates of remission
in persons with schizophrenia.
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In recent years there has been an emphasis on meaning-
ful clinical outcomes as well as focus on functional
recovery in mental health. In schizophrenia, complete
recovery implies the ability to function in the commu-
nity, socially and vocationally, as well as being relatively
free of disease-related symptomatology [1]. A consensus* Correspondence: mdybarak@netvision.net.il
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distribution, and reproduction in any mediumproposal by Andreasen et al. [2] presented criteria to
define symptomatic remission in schizophrenia. The
group proposed that symptom remission be based on
maintenance of low level of symptoms for at least
6 months in psychoticism, disorganization, and negative
symptoms. Since the publication of the Remission in
Schizophrenia Working Group symptomatic remission
criteria (RSWG) scale in 2005 many studies have
employed this instrument to assess the characteristics
and epidemiology of symptomatic remission amongst
persons with schizophrenia. The results of these studies
emphasize that the remission concept appears to be
achievable and is not just an academic definition. MoreCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 The PSRS scale
Severity PSRS items
1 2 3 4 5 6 7 Impaired Familial Relations
1 2 3 4 5 6 7 Impaired Understanding and Self- awareness
1 2 3 4 5 6 7 Impaired Energy
1 2 3 4 5 6 7 Impaired Interest in daily life
1 2 3 4 5 6 7 Impaired Self-care
1 2 3 4 5 6 7 Impaired Activism
1 2 3 4 5 6 7 Impaired Responsibility Medical Treatment
1 2 3 4 5 6 7 Impaired Use of Community Services
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meet the full symptomatic remission criteria [3].
Consensus-defined standards for symptomatic remis-
sion in persons with schizophrenia have been the focus
of clinical and research interest in the last decade [2].
Such standards provide clarity for treatment goals, as
well as a framework for the design and comparison of
investigational trials and the assessment of the effective-
ness of pharmacological and psychosocial interventions.
It is accepted that impairments in everyday living skills
are present in persons with schizophrenia and the
current diagnostic criteria of schizophrenia includes sev-
eral references to functioning. The alleviation of schizo-
phrenia symptoms, which has clearly improved with the
development of antipsychotic medications with greater
efficacy, does not necessarily mirror a similar alleviation
of functional impairments. Symptomatic and psycho-
social remissions appear to be different domains, repre-
senting two steps towards recovery that do not
necessarily overlap [4]. Persons with schizophrenia are
capable of achieving symptomatic remission and high
levels of social functioning [1]. Psychosocial function
and dysfunction are of critical importance in achieving
remission yet there is still a scarcity of studies addressing
this issue using formal quantifiable rating scales.
We have recently developed the Psychosocial Remis-
sion in Schizophrenia (PSRS) Scale - an 8-item scale
quantifying psychosocial remission in schizophrenia [5].
The PSRS is a user-friendly clinician rated scale for the
assessment of psychosocial remission in schizophrenia
that complements the Remission in Schizophrenia
Working Group scale [2]. Psychiatric case managers
rated psychosocial remission using the PSRS and clinical
remission using the Remission in Schizophrenia Work-
ing Group symptomatic remission criteria (RSWG). The
aim of the present study was to quantify both symptom-
atic and psychosocial remission in a national sample of
community dwelling persons with schizophrenia using
these validated and accepted rating scales. The study
reflects between-groups comparison of antipsychotic med-
ications and oral versus depot long acting preparations
administration methods on the outcome of remission.
Method
The 2005 APA Remission in Schizophrenia Working
Group (RSWG) concluded that any definition of remis-
sion in schizophrenia should include a significant time
component and be applicable to patients across stages of
disease course. A symptom-based, validated assessment
instrument was developed to enable clinicians and
researchers to define symptomatic remission through-
out the course of illness [2]. In brief, this instrument
proposed using 8 items from either (a) the PANSS; or
(b) the Scale for Assessment of Positive Symptoms(SAPS) and Scale for Negative Symptoms (SANS); or
(c) the Brief Psychiatric Rating Scale (BPRS). These pro-
posed criteria were put forward to ensure that three
dimensions of psychopathology are to be assessed – Psy-
choticism, Disorganization and Negative symptoms [6].
A patient suffering from schizophrenia is defined as
being in remission if for the past 6 months he/she
scored mild/minimal/absent on each of the 8 items of
the symptomatic remission scale (RSWG).
The Israel Psychiatric Association has decided to
adopt this approach. A task force was formed to develop
the PSRS and was instructed that it should create a tool
to complement the RSWG so that it too include 8 items,
each scored from 1 – absent, to: 7 – extreme. A ques-
tions’ bank was reviewed by 429 mental health profes-
sionals – psychiatrists, residents, psychiatric nurses,
and community nurses. Four items were found to be
most frequently sanctioned in the quality-of-life domain
(familial relations, understanding and self-awareness,
energy and interest in everyday life). Four items were
sanctioned in the instrumental activities of daily living
domain (self-care, activism, responsibility for medica-
tions and use of community services). The inter-rater
reliability for each of the 8 PSRS items was calculated
(interclass correlation) to be as follows: item 1 – 0.83;
item 2 – 0.68; item 3 – 0.66; item 4 – 0.70; item
5 – 0.67; item 6 – 0.78; item 7 – 0.76 and item 8 – 0.68.
In addition the dichotomous distinction between “in-
remission” (scoring 1, 2 or 3 on each item) or “non-
remission” (scoring 4 or higher) was computed. The
mean frequency of correlated score was 80% ranging
from 64% for the “Impaired Activism” item to 90% for
the “Impaired Understanding and Self- awareness” item.
Interrater reliability among 70 psychiatrists ranged from
0.67 to 0.83. [For detailed description of the PSRS see
(Barak et al, 2010; Ref., [5])].
A survey questionnaire was designed consisting of
3 sections: a) clinical and demographic variable; b) the
RSWG scale and c) the PSRS (See Table 1). Survey
questionnaires were distributed in community mental
health centers across the country. All healthcare survey
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complete the rating of both scales following an interview
with the patient. Psychiatric case managers rated psy-
chosocial remission using the PsychoSocial Remission
Scale (PSRS) and clinical remission using the Remission
in Schizophrenia Working Group symptomatic remis-
sion criteria (RSWG). The target population for partici-
pation in this survey was composed of persons with
schizophrenia fulfilling the following criteria: 1) DSM-IV
diagnosis of schizophrenia, 2) age 18 years or older,
3) no psychiatric hospitalization or a minimum of
6 months following discharge from inpatient psychiatric
care, 4) a mental health professional case-manager in
charge of the patient for a minimum of 6 months and
5) no change in psychotropic medications in the 4 weeks
preceding the survey evaluation.
Participants in the present survey were psychiatrists,
registered nurses and social workers who were case
managers of persons with schizophrenia in community
mental health centers across the country.
This study was approved by the Abarbanel MHC
Internal Review Board.
Statistical analysis
Data analyzes was carried out with the use of the Statis-
tical Analysis System software, SAS Institute. The non-
parametric sign-rank test method was employed. The
t-test and a non-parametric test were undertaken to
assess differences between the evaluations for continuous
variables (age, scales score). Differences between categor-
ical parameters were tested according to the McNemar
test for dependent (matched) populations (gender, case
manager profession, dichotomous definition of remis-
sion). We employed the non-parametric test as a “con-
servative” test to ensure analyses in case of skewed data.
All tests applied were two-tailed, and p value of 5% or
less was considered statistically significant.
Results
A total of 445 survey questionnaires were endorsed and
analyzed in the present study. The majority (268/445;
60%) of case-managers endorsing the questionnaire
were psychiatrists. Nurses comprised more than a third
of the respondents (161/445; 36%) and social workers
only 4% (16/445). The proportion of case managers
reflects the employment in Israel within the public
mental health sector.
Patients characteristics were as follows: mean age
43.4 + 13.1 years; 61% (N= 271) were men and 39%
(N= 174) were women. The most common form of anti-
psychotic treatment was oral medications (55%; N= 235)
followed by Intra Muscular (IM) long acting first gener-
ation antipsychotic medications (23%; N= 98) closely
followed by IM long acting risperidone (22%; N= 97).There were 15 patients who had been treated by a com-
bination of IM long acting antipsychotic augmented
by an oral preparation. These were excluded from the
final analysis.
Symptomatic remission
Of the 445 patients 37% (N= 165) achieved symptomatic
remission as assessed by the RSWG scale (mean score
22.8 + 10.6). Rates of symptomatic remission were sig-
nificantly higher in patients treated by IM long acting
first generation antipsychotic medications and IM long
acting risperidone compared with oral medications (51%
and 48% vs., 29% respectively, p = 0.0003).
PsychoSocial remission
Of the 445 patients 31% (N= 138) achieved psychosocial
remission as assessed by the PSRS scale (mean score
26.3 + 11.8). Rates of symptomatic remission were sig-
nificantly higher in patients treated by IM long acting
first generation antipsychotic medications and IM long
acting risperidone compared with oral medications (43%
and 41% vs., 24% respectively, p = 0.0003).
No statistically significant differences or trends were
observed in either symptomatic or psychosocial remis-
sion for analysis by gender, age or by profession of case
manager (physician, nurse or social worker).
The two items of the PSRS scale most frequently quan-
tified as denoting remission were “impaired self care”
and “impaired responsibility for medical treatment.”
Non-remitted patients
Although remission was defined dichotomously for the
purpose of analyses in the present study, it is important
to report how the rest of the sample’s scores were dis-
tributed amongst participants. It is of note that women
had achieved higher rates of both symptomatic and
psychosocial remission than men; 39.5% vs., 36.6% and
34.9% vs., 28.4%, respectively. Post-hoc deletion of the
“6 months duration” criteria for remission resulted in
lower remission rates for both symptomatic remission
(25%) and psychosocial remission (29.5%). Finally, the
distribution of remission scores emphasizes that 29.7%
of patients were lacking only 2 to 3 points in order to
reach the “dichotomous” definition of either symptom-
atic or psychosocial remission.
Comparison of remitted and non-remitted patients
according to medication
Patients differed in remission status according to anti-
psychotic medication as follows: a) Oral medications –
51% of remitted patients vs., 49% of non-remitted,
b) FGA long acting – 68% of remitted vs., 32% of non-
remitted and c) Risperidone long acting – 65% of remit-
ted vs., 35% of non-remitted.
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In the present study, a large national survey amongst
community dwelling persons with schizophrenia
employed two complementary scales to quantify both
symptomatic and psychosocial remission rates. The
rates of symptomatic remission in the present survey
(37%) are in line with recent publications focusing on
remission. Haro and colleagues conducted a one - year
observational study in Europe following more than
6,500 patients reporting that 38% achieved symptomatic
remission [7]. De Hert and colleagues evaluated in a
naturalistic prospective study persons with schizophrenia
in different treatment settings. In this sample of 341
patients 29% met criteria for symptomatic remission at
study endpoint [8]. Recently, Lambert and colleagues
aimed to measure symptomatic and functional remission
in patients treated with long-acting injectable risperi-
done. Among 529 patients from seven European coun-
tries, symptomatic remission lasting 6 months or longer
occurred at some point during treatment in 33% of
patients [9]. In the present survey patients who were
treated by long-acting injectable antipsychotics –
whether first or second generation - were noted to
achieve higher rates of symptomatic remission than
patients receiving oral antipsychotic treatment. One pos-
sible interpretation of these findings is that improved
adherence frequently reported with long acting antipsy-
chotics is associated with remission [10]. However,
schizophrenia patients with unstable disease may not
fully benefit from this advantage of injectable long-
acting antipsychotics [11]. Thus, both the fact that
patients in the present study had a case manager and
the fact that they were not at imminent risk for
hospitalization but rather stable at baseline receiving
community mental health services, help explain the dif-
ferences in remission rates between studies.
Evaluating only clinically pathological signs and symp-
toms does not capture the full range of remission in per-
sons with schizophrenia as social and psychological
aspects of their lives may be underrepresented in such
evaluations. One of the major aspects of remission is
patients’ ability to adapt to the demands of society, but
may be harder to achieve than symptomatic stability
[12]. Previous social functioning has consistently been
found to be a good predictor of future social functioning
in schizophrenia. This may be explained by the protect-
ive role of social networks [13]. The employment of psy-
chosocial outcomes in studies of schizophrenia patients
may elevate the threshold for remission. It has been
demonstrated that although psychiatric treatment effect-
ively reduces severity of psychotic symptoms, the major-
ity of patients do not have a satisfactory level of social
functioning [14]. Indeed, in the present survey rates of
psychosocial remission were lower than for symptomaticremission. This is in accordance with other publications
demonstrating that combined symptomatic, functional,
and quality-of-life remission was observed only in one in
five schizophrenia patients [9].
Contemporary research examines dysfunction among
the lives of persons with schizophrenia as a matter of
the impact of biological and social forces [15,16]. While
literature from a range of sources has explored self-
experience in schizophrenia it remains unclear whether
these differing views of self-experience are comparable
with one another. There is a wide-ranging, if general
consensus, which suggests that many persons with
schizophrenia experience themselves as diminished rela-
tive to their former selves. Within this broad consensus,
significant disagreements exist and recent work suggests
a program of research to address these disagreements
[15]. Recovery is a versatile concept, and the need for
its’ quantification in practice has been identified. An
analysis of 30 international proposals offering recovery-
oriented practice guidance was conducted in 2011. The
emerging conceptual framework consists of 16 central
themes, grouped into four domains: promoting citizenship,
organizational commitment, supporting personally defined
recovery, and working relationship. A key challenge for
professionals is the lack of clarity about what constitutes
recovery-oriented practice [16]. The combination of clin-
ical and psychosocial domains undertaken in the present
study may contribute to a better defined recovery.
Recovery is increasingly a focus in mainstream psych-
iatry. However, it has also become clear that the concept
lacks a strong scientific basis. One of the main concep-
tual issue that has not received sufficient attention in the
literature is the role of evidence-based practices in
recovery-oriented care [17]. Investigations as to the rela-
tion between objective clinical recovery as defined by
symptom severity and level of functioning, and subject-
ive personal recovery as defined by quality of life,
domains of personal confidence and hope, willingness
to ask for help and reliance on others have been sparse.
Silverstein & Bellack addressed this issue recently, con-
cluding that that clinical objective recovery is not syn-
onymous with personal subjective recovery yet can be
conceptualized as complementary [18]. The present
study is in accord with the construct of recovery put for-
ward by these authors as involving both objective and
subjective elements [17,18].
Several demographic, clinical, and methodological
variables are uncontrolled for in the analyses between
drug treatments, limiting the conclusions that can be
drawn from this survey. Duration of illness, number of
hospitalizations, lifetime exposure to antipsychotic drug
dosage and socioeconomic status are unreported. All of
these variables, or some combination of these, may have
influenced the present study’s results. In addition, it can
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ager may have affected the results instead of the medica-
tion itself, differing capacity for metacognition and other
variables not captured in this brief survey. Finally, the
generalizability of the findings given the restricted sam-
ple used must be viewed cautiously.
Conclusion
In conclusion, the rates of symptomatic remission cap-
tured in this national survey are similar to those
reported from other countries. To the best of our know-
ledge this is the first study to report rates of psychosocial
remission using a validated rating scale. Psychosocial re-
mission rates were found to be lower than symptomatic
remission underlining the need to address this issue
through a variety of interventions. As we do not yet have
a complete understanding of factors affecting psycho-
social remission, adherence may be proposed as a con-
tributing factor. IM long acting preparations in the
present survey were associated with higher remission
rates, and thus treatment choice may influence rates of
remission in schizophrenia patients. It must be stressed
that a variety of non-pharmacological interventions as
well as a range of empirically validated psychosocial
approaches are employed in achieving remission for per-
sons with schizophrenia.
To support these preliminary findings prospective
studies quantifying symptomatic and psychosocial remis-
sion are called for.
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